Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313001 · ClinicalTrials.gov registry record · Phase 3
Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 373
- Enrollment target
NCT00313001 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 373 participants.
The verdict
NCT00313001, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 373 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The study will compare A1C reduction achieved in patients receiving biphasic insulin aspart 70/30 once or twice daily to patients receiving exenatide twice daily. Patients enrolled in the study will be insulin naive patients who have not achieved glycemic control with metformin and sulfonylurea.
Interventions
- DRUG biphasic insulin aspart
- DRUG exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 373 participants |
| Start Date | 2006-04 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00313001
The ClinicalTrials.gov registry entry for NCT00313001 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 373 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which biphasic insulin aspart is the first listed.
NCT00313001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00313001 about?
NCT00313001 is a clinical study titled "Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.". This trial is conducted in the United States of America (USA). The study will compare A1C reduction achieved in patients receiving biphasic insulin aspart 70/30 once or twice daily to patients receiving exenatide twice daily. Patients enrolled in the study will be insulin naive patients who have not...
What is the current status of trial NCT00313001?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 373 participants. The study started on 2006-04. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00313001?
The interventions under investigation include: biphasic insulin aspart (DRUG), exenatide (DRUG).
Who is sponsoring clinical trial NCT00313001?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.